Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01127438
Recruitment Status : Completed
First Posted : May 20, 2010
Results First Posted : February 8, 2013
Last Update Posted : February 8, 2013
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of LUSEDRA (fospropofol disodium) and to determine whether a dose lower than currently approved can provide effective moderate sedation required to complete diagnostic or therapeutic procedures.

Condition or disease Intervention/treatment Phase
Sedation Drug: fospropofol disodium Subgroup 1 Lower Dose Drug: fospropofol disodium Subgroup 1 Approved Dose Drug: fospropofol disodium Subgroup 2 Lower Dose Drug: fospropofol disodium Subgroup 2 Approved Dose Drug: fospropofol disodium Subgroup 3 Lower Dose Drug: fospropofol disodium Subgroup 3 Approved Dose Phase 4

Detailed Description:
This will be a double-blind, randomized, parallel-group, multicenter, dose-ranging study, in age >/= 65 years, and/or weight < 60 kg, and/or American Society of Anesthesiologists (ASA) Physical Classification Status 3 or 4 subjects using either the approved dose modification or 1 lower dose, to achieve a moderate level of sedation required to complete the scheduled diagnostic or therapeutic procedure. Three subgroups of subjects will be included. For Subgroup 1 and Subgroup 2, approximately equal numbers of subjects will be enrolled into 2 strata: weight >/= 55 kg and weight < 55 kg. For Subgroup 1 and Subgroup 2, subjects will be randomly assigned to 1 of 2 dose groups in a 1:1 ratio within each stratum. For Subgroup 3, subjects will be randomly assigned to 1 of 2 dose groups in a 1:1 ratio.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 153 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations
Study Start Date : April 2010
Actual Primary Completion Date : June 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Colonoscopy

Arm Intervention/treatment
Active Comparator: fospropofol disodium Subgroup 1 Lower Dose Drug: fospropofol disodium Subgroup 1 Lower Dose
Dose of Initial IV (Titration) Bolus 6.5mg/kg) (administered to Subgroup 1, Weight < 60 kg and Age < 65 years and ASAI and II)

Active Comparator: : fospropofol disodium Subgroup 1 Approved Dose Drug: fospropofol disodium Subgroup 1 Approved Dose
(Dose of Initial IV (Titration) Bolus 385mg) (Administered to Subgroup 1, Weight <60 kg and Age <65 years and ASAI and II)

Active Comparator: fospropofol disodium Subgroup 2 Lower Dose Drug: fospropofol disodium Subgroup 2 Lower Dose
Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (administered to Subgroup 2, Weight < 60 kg and Age >/=65 years and ASA 3 or 4

Active Comparator: fospropofol disodium Subgroup 2 Approved Dose Drug: fospropofol disodium Subgroup 2 Approved Dose
(Dose of Initial IV (Titration) Bolus 297.5mg) (Administered to Subgroup 2, Weight <60 kg and Age >/=65 years and ASA 3 or 4

Active Comparator: fospropofol disodium Subgroup 3 Lower Dose Drug: fospropofol disodium Subgroup 3 Lower Dose
(Dose of Initial IV (Titration) Bolus 3.9mg/kg) (Administered to Subgroup 3, Weight >/= 60 kg and Age >/= 65 years and ASA 3 or 4

Active Comparator: fospropofol disodium Subgroup 3 Approved Dose Drug: fospropofol disodium Subgroup 3 Approved Dose
Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (Administered to Subgroup 3, Weight >/= 60 kg and Age >/= 65 years and ASA 3 or 4




Primary Outcome Measures :
  1. Number of Participants With Sedation Success [ Time Frame: Day 1 ]
    Sedation success was defined as subjects who met the following 4 criteria: had 3 consecutive Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores at or less than 4 after administration of sedative medication, completed the procedure, did not require the use of alternative sedative medication, and did not require manual/mechanical ventilation. The MOAA/S score was used to clinically rate the level of sedation using a score of 0 to 5 based on the subject's level of responsiveness. A high score on the MOAA/S scale indicated a lower level of sedation.


Secondary Outcome Measures :
  1. Number of Participants With Treatment Success [ Time Frame: Day 1 ]
    Treatment success was defined as subjects who met the following 3 criteria: completed the procedure, did not require the use of alternative sedative medication, and did not require manual/mechanical ventilation.

  2. Number of Participants With Modified Sedation Success [ Time Frame: Day 1 ]
    Modified sedation success was defined as a subject who was a sedation success and did not have a MOAA/S score <2 any time after administration of sedative medication. Sedation success was defined as subjects who had 3 consecutive MOAA/S scores at or less than 4 after administration of sedative medication, completed the procedure, did not require the use of alternative sedative medication, and did not require manual/mechanical ventilation. The MOAA/S score was used to clinically rate the level of sedation using a score of 0 to 5 based on the level of responsiveness.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Subjects who meet all of the following criteria will be included in the study:

  1. Male and female adult candidates for diagnostic or therapeutic colonoscopy with at least one of the following characteristics:

    • Subgroup 1: Weight < 60 kg and age >/= 18 to < 65 years and ASA I or II;
    • Subgroup 2: Weight < 60 kg and age >/= 65 years and/or ASA 3 or 4; or
    • Subgroup 3: Weight >/=60 kg and age >/= 65 years and/or ASA 3 or 4.
  2. Females of childbearing potential must have a negative beta human chorionic gonadotropin (?hCG) urine pregnancy test at Visit 1 (Screening) and prior to starting study drug (Visit 2). Female subjects of childbearing potential must agree to be abstinent or to use a highly effective methods of contraception (eg, condom + spermicide, condom + diaphragm with spermicide, intrauterine device [IUD], or have a vasectomised partner) having starting for at least 1 menstrual cycle prior to starting study drug and throughout the entire study period and for 30 days after the last dose of study drug. Those women using hormonal contraceptives must also be using an additional approved method of contraception (as described previously). Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential;
  3. Are willing and able to comply with all aspects of the protocol; and
  4. Provide written informed consent.

Subjects who meet any of the following criteria will be excluded from participation in the study:

  1. Females who are pregnant (positive BhCG urine pregnancy test) or breastfeeding;
  2. Subjects who do not meet nil per os (NPO) requirement of no solid foods within 8 hours and clear fluids up to 3 hours before the procedure (assessed only at Baseline);
  3. Evidence of clinically significant disease or a history of a concomitant medical condition (eg, cardiac, respiratory, gastrointestinal, renal disease) that, in the opinion of the Investigator, could affect the subject's safety or ability to safely complete the study;
  4. Subjects with hypersensitivity to LUSEDRA or any other components of LUSEDRA, including its active metabolite, propofol;
  5. History of drug or alcohol dependency or abuse within approximately the last 2 years; or
  6. The Investigator believes to be medically unfit to receive the study drug or unsuitable for any other reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01127438


Locations
Show Show 23 study locations
Sponsors and Collaborators
Eisai Inc.
Investigators
Layout table for investigator information
Study Director: Jim Ferry Eisai Inc.
Layout table for additonal information
Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT01127438    
Other Study ID Numbers: E2083-A001-406
First Posted: May 20, 2010    Key Record Dates
Results First Posted: February 8, 2013
Last Update Posted: February 8, 2013
Last Verified: February 2013
Keywords provided by Eisai Inc.:
Monitored anesthesia care sedation
Additional relevant MeSH terms:
Layout table for MeSH terms
Fospropofol
Propofol
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Intravenous
Anesthetics, General
Anesthetics